INZY
Income statement / Annual
Last year (2024), Inozyme Pharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Inozyme Pharma, Inc.'s net income was -$102.02 M.
See Inozyme Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$1.29 M
|
$1.18 M
|
$1.05 M
|
$217.00 K
|
$83.00 K
|
$26.00 K
|
| Gross Profit |
$0.00
|
-$1.29 M
|
-$1.18 M
|
-$1.05 M
|
-$217.00 K
|
-$83.00 K
|
-$26.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$83.23 M
|
$54.05 M
|
$47.85 M
|
$37.72 M
|
$46.49 M
|
$16.22 M
|
$8.10 M
|
| General & Administrative Expenses |
$20.80 M
|
$20.80 M
|
$20.83 M
|
$18.93 M
|
$10.55 M
|
$4.59 M
|
$3.49 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.80 M
|
$20.80 M
|
$20.83 M
|
$18.93 M
|
$10.55 M
|
$4.59 M
|
$3.49 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$319.00 K
|
-$189.00 K
|
$247.00 K
|
-$24.00 K
|
$0.00
|
| Operating Expenses |
$104.03 M
|
$75.65 M
|
$68.68 M
|
$56.65 M
|
$57.04 M
|
$20.81 M
|
$11.59 M
|
| Cost And Expenses |
$0.00
|
$75.65 M
|
$68.68 M
|
$56.65 M
|
$57.04 M
|
$20.81 M
|
$11.59 M
|
| Interest Income |
$7.67 M
|
$7.84 M
|
$1.93 M
|
$211.00 K
|
$370.00 K
|
$1.11 M
|
$284.00 K
|
| Interest Expense |
-$5.56 M
|
$3.33 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3.55 M
|
$833.00 K
|
$1.18 M
|
$1.05 M
|
$217.00 K
|
$83.00 K
|
$26.00 K
|
| EBITDA |
-$104.03 M |
-$74.81 M |
-$65.88 M |
-$55.97 M |
-$56.82 M |
-$20.72 M |
-$11.57 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.01 M
|
$4.48 M
|
$1.61 M
|
$22.00 K
|
$617.00 K
|
$1.08 M
|
$4.63 M
|
| Income Before Tax |
-$102.02 M
|
-$71.17 M
|
-$67.06 M
|
-$56.62 M
|
-$56.42 M
|
-$19.72 M
|
-$6.96 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$102.02 M
|
-$71.17 M
|
-$65.45 M
|
-$56.41 M
|
-$55.84 M
|
-$18.62 M
|
-$6.96 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.62 |
-1.37 |
-1.73 |
-2.39 |
-2.39 |
-1.23 |
-0.46 |
| EPS Diluted |
-1.62 |
-1.37 |
-1.73 |
-2.39 |
-2.39 |
-1.23 |
-0.46 |
| Weighted Average Shares Out |
$62.81 M
|
$51.84 M
|
$37.76 M
|
$23.56 M
|
$23.38 M
|
$15.16 M
|
$15.14 M
|
| Weighted Average Shares Out Diluted |
$62.81 M
|
$51.84 M
|
$37.76 M
|
$23.56 M
|
$23.38 M
|
$15.16 M
|
$15.14 M
|
| Link |
|
|
|
|
|
|
|
